Oramed submits request for new U.S. oral insulin trial; Analysts expect the inhalation market to reach $47M by 2017;

> Oramed ($ORMP) submitted a pre-IND meeting request to the FDA for a U.S. trial of its oral insulin capsule, ORMD-0901. Release

> Industry analysts concluded that inhalation drug delivery systems are gathering momentum with the development of faster acting and more effective products, with the global market expected to reach $47 billion by 2017. Release

> Catalent bought Chinese softgel firm Zhejiang Jiang Yuan Tang Biotechnology, building upon its existing softgel network in Asia Pacific, including facilities in Japan and Australia. More

> Bespak Europe won government funding to the tune of up to £1 million ($1.52 million) from the U.K.'s Department of Health to develop a new bolus drug delivery device entering Phase II. Article

> Oxford Pharmascience extended its collaboration with University College London to further develop its drug-delivery compounds, giving Oxford the option on over 53 compounds to commercialize with the university. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.